|Product||Clinical Indication||Phase of Development||Partner||Anticipated Newsflow|
|Prevascar||Reduction of skin scarring||Phase 2||-||H1 2012 Proof of concept clinical trial in African subjects reports final data.|
|Juvidex||Improve skin appearance and promote healing of damaged skin||Cosmetic ingredient||-|
Prevascar (an intradermal injectable solution of human recombinant Interleukin 10) previously reported a positive exploratory efficacy trial for the reduction of scarring in the skin. Following improvements in the manufacturing of Prevascar drug substance and product, and identification of a clinical cohort who are predicted (on the basis of a non-drug experimental surgery study) to benefit particularly well from Prevascar's modulating effect on the wound inflammatory response, Renovo has commenced a new proof of concept clinical trial in skin excisions and excisions in African-ancestral group human volunteers and is due to report final data in H1 2012.
Juvidex (topical application of Mannose-6-Phosphate (M-6-P)) reported statistically significant improvements in pre-specified endpoints of skin appearance and acceleration of healing in a proof of concept clinical trial. Renovo intends to sell the Juvidex programme to a partner from the cosmetic industry.